Posted by Michael Wonder on 27 Feb 2024
GSK's RSV vaccine, Arexvy, accepted for review by Health Canada for prevention of RSV disease in adults aged 50-59 at increased risk
26 February 2024 - Submission supported by positive results of a Phase 3 study showing immune response and tolerability in adults aged 50-59.
GSK has submitted a supplementary new drug submission to Health Canada to expand the use of Arexvy, GSK's respiratory syncytial virus vaccine (recombinant, AS01E adjuvanted), to include adults aged 50-59 at increased risk for respiratory syncytial virus disease.
